Ganoderic Acid A
(Synonyms: 灵芝酸 A) 目录号 : GN10109
Ganoderic Acid A是一种来源于灵芝（Ganoderma lucidum）的三萜类化合物，具有多种生物活性。
Cas No.:81907-62-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ganoderic Acid A is a triterpenoid compound derived from Ganoderma lucidumand exhibits multiple biological activities[1-2]. Ganoderic Acid A possesses inhibitory effects against cancer, oxidation, and aging, among others[3-4].
In vitro, concurrent treatment of BV2 microglial cells with Ganoderic Acid A (50μg/ml) and LPS (0.5μg/ml) for 24 hours significantly suppressed LPS-induced proliferation and activation of BV2 microglia, and promoted the polarization of microglia from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype[5]. Treatment of MC3T3-E1 cells (induced with 1mM H₂O₂) and primary osteoblasts (induced with 250μM H₂O₂) with Ganoderic Acid A (5–80μM) for 24 hours significantly promoted osteogenic differentiation and mineralization nodule formation, and upregulated the protein expression of osteogenesis-related markers RUNX2, OPN, and β-catenin[6].
In vivo, intraperitoneal administration of Ganoderic Acid A (20–40mg/kg) 1 hour before Ovalbumin (0.1g) challenge in OVA-sensitized BALB/c mice significantly alleviated airway hyperresponsiveness and reduced the total number of inflammatory cells in bronchoalveolar lavage fluid[7]. Daily administration of Ganoderic Acid A (20mg/kg/d) via intraperitoneal injection or topical application for 6 days in Imiquimod (62.5mg per mouse)-induced psoriasiform dermatitis BALB/c mice significantly ameliorated skin erythema, thickening, and scaling, and lowered the Psoriasis Area and Severity Index (PASI) score[8].
References:
[1] Sui Q, Zhu C, Shi S, et al. Ganoderic acid A: an in-depth review of pharmacological effects and molecular docking analysis. J Ethnopharmacol. 2025 Jun 12;349:119868.
[2] Ma F, Wang J, Jiang W, et al. Ganoderic Acid A: A Potential Natural Neuroprotective Agent for Neurological Disorders: A Review. Int J Med Mushrooms. 2024;26(2):11-23.
[3] Zhang X, Huang S, Xu H, et al. Research progress on plant-derived natural compounds regulating the MAPK signaling pathway for the prevention and therapy of Alzheimer's disease. Front Pharmacol. 2025 Sep 19;16:1666082.
[4] Song Z, Wang C, Ding F, et al. Ganoderic Acid A Enhances Tumor Suppression Function of Oxaliplatin via Inducing the Cytotoxicity of T Cells. Anticancer Agents Med Chem. 2023;23(7):832-838.
[5] Jia Y, Zhang D, Yin H, et al. Ganoderic Acid A Attenuates LPS-Induced Neuroinflammation in BV2 Microglia by Activating Farnesoid X Receptor. Neurochem Res. 2021 Jul;46(7):1725-1736.
[6] Zhao J, Fan Y, Li H, et al. Ganoderic Acid A Prevented Osteoporosis by Modulating the PIK3CA/p-Akt/TWIST1 Signaling Pathway. Food Sci Nutr. 2025 Apr 14;13(4):e70177.
[7] Lu X, Xu C, Yang R, et al. Ganoderic Acid A Alleviates OVA-Induced Asthma in Mice. Inflammation. 2021 Oct;44(5):1908-1915.
[8] Xiao C, Chen J, Zhou X, et al. Ganoderic acid A alleviate psoriasis by inhibiting GSDMD-mediated pyroptosis. Tissue Cell. 2025 Dec;97:103078.
Ganoderic Acid A是一种来源于灵芝（Ganoderma lucidum）的三萜类化合物，具有多种生物活性[1-2]。Ganoderic Acid A具有抑制癌症、抗氧化、抗衰老等的作用[3-4]。
在体外，Ganoderic Acid A(50μg/ml)与LPS(0.5μg/ml)同时处理BV2小胶质细胞24小时，显著抑制LPS诱导的BV2小胶质细胞增殖和活化，并促进小胶质细胞由促炎的M1表型向抗炎的M2表型转化[5]。Ganoderic Acid A(5–80μM)处理MC3T3-E1（经1mM H2O2诱导）细胞和原代成骨细胞（经250μM H2O2诱导）24小时，显著促进成骨分化和矿化结节形成，并上调成骨相关标志物RUNX2、OPN和β-catenin的蛋白表达[6]。
在体内，Ganoderic Acid A（20–40mg/kg）于Ovalbumin（0.1g）激发前1小时腹腔注射处理OVA致敏的BALB/c小鼠，显著减轻哮喘小鼠气道高反应性，并降低支气管肺泡灌洗液中炎症细胞总数[7]。Ganoderic Acid A（20mg/kg/d）通过腹腔注射或局部外用于Imiquimod（62.5mg/只）诱导的银屑病样皮炎BALB/c小鼠6天，显著减轻皮肤红斑、增厚和鳞屑，并降低银屑病面积和严重程度指数（PASI）评分[8]。
| Cell experiment [1]: | |
|
Cell lines |
BV2 microglial cells (murine microglial cell line) |
|
Preparation Method |
BV2 cells were cultured in DMEM high glucose medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37°C under 5% CO₂. Cells were treated with Ganoderic Acid A at 50μg/mL concurrently with LPS (0.5μg/mL) for 24 hours. |
|
Reaction Conditions |
50μg/mL; 24h |
|
Applications |
Ganoderic Acid A significantly suppressed LPS-induced BV2 microglial proliferation and activation. Ganoderic Acid A promoted the polarization of microglia from pro-inflammatory M1 to anti-inflammatory M2 phenotype. |
| Animal experiment [2]: | |
|
Animal models |
Female BALB/c mice |
|
Preparation Method |
Mice were sensitized by intraperitoneal injection of 10mg Ovalbumin (OVA) + 1mg aluminum hydroxide in saline on days 1, 7, and 14. From day 21, they received daily OVA aerosol challenges (0.1g OVA in 10ml saline, 30min) for 7 days. Ganoderic Acid A (20 or 40mg/kg) was administered intraperitoneally 1 hour before each OVA challenge. Lung tissues and serum were collected after the final challenge for analysis. |
|
Dosage form |
20 or 40mg/kg; i.p.; Daily for 7 days. |
|
Applications |
Ganoderic Acid A significantly attenuated OVA-induced airway hyperreactivity (AHR), reduced inflammatory cell infiltration (eosinophils, lymphocytes, neutrophils) in serum and lung tissue, and decreased levels of Th2 cytokines (IL-4, IL-5, IL-13) and IgE in serum. Ganoderic Acid A also suppressed TLR4/NF-κB signaling pathway activation, as evidenced by reduced expression of TLR4, MyD88, p-NF-κB, and p-IκBα in lung tissues. |
|
References: |
|
| Cas No. | 81907-62-2 | SDF | |
| 别名 | 灵芝酸 A | ||
| 化学名 | (2R,6R)-6-[(5R,7S,10S,13R,14R,15S,17R)-7,15-dihydroxy-4,4,10,13,14-pentamethyl-3,11-dioxo-2,5,6,7,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid | ||
| Canonical SMILES | CC(CC(=O)CC(C)C(=O)O)C1CC(C2(C1(CC(=O)C3=C2C(CC4C3(CCC(=O)C4(C)C)C)O)C)C)O | ||
| 分子式 | C30H42O7 | 分子量 | 514.65 |
| 溶解度 | DMF: 5mg/mL,DMSO: 1 mg/mL,Ethanol: 3 mg/mL | 储存条件 | 4°C, away from moisture and light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9431 mL | 9.7153 mL | 19.4307 mL |
| 5 mM | 388.6 μL | 1.9431 mL | 3.8861 mL |
| 10 mM | 194.3 μL | 971.5 μL | 1.9431 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet